Alector reports inducement grants as permitted by the nasdaq listing rules

South san francisco, calif., may 27, 2022 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of alector's board of directors granted gary romano, m.d., ph.d., the company's newly-hired chief medical officer, an inducement equity grant on may 27, 2022, consisting of inducement stock options to purchase an aggregate of 369,000 shares of the company's common stock and inducement restricted stock units, or rsus, covering an aggregate of 92,250 shares of the company's common stock. these inducement stock options and inducement rsus are subject to the terms of alector's 2022 inducement equity incentive plan and related forms of agreements and were granted as inducements material to new employees entering into employment with alector in accordance with nasdaq listing rule 5635(c)(4).
ALEC Ratings Summary
ALEC Quant Ranking